HSBC Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $920

Benzinga Newsdesk www.benzinga.com Positive 80.9%

Neg 0% Neu 0% Pos 80.9%

HSBC analyst Rajesh Kumar maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $800 to $920.